Ken Griffin Atreca, Inc. Call Options Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	SELL	$0.88 - $1.22 $4,576 - $6,344	-5,200 Reduced 32.91%	10,600 $10,000
Q1 2023 May 15, 2023	SELL	$0.91 - $1.82 $59,605 - $119,210	-65,500 Reduced 80.57%	15,800 $18,000
Q4 2022 Feb 14, 2023	SELL	$0.78 - $1.68 $6,318 - $13,608	-8,100 Reduced 9.06%	81,300 $65,000
Q3 2022 Nov 14, 2022	BUY	$1.59 - $2.74 $93,492 - $161,112	58,800 Added 192.16%	89,400 $140,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.